Choose Your News
Loading...
Thumbnail
CAMBRIDGE, Mass., Nov. 09, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development. [Read More]
CAMBRIDGE, Mass., Nov. 08, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development. [Read More]
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $2.70, or 5 percent, at $53.74 in Friday's session. Investors have been slow to ... [Read More]
Executive Director, Corporate Affai... [Read More]
Sarepta Therapeutics Inc. ... [Read More]
Thumbnail
Xylem Inc. (XYL), Sarepta Therapeutics, Inc. (SRPT) ... [Read More]
Morgan Stanley upgraded Sarepta Therapeutics Inc. (Nasdaq: SRPT) from and Equal Weight rating to an Overweight rating and lifted its price target from $33.00 to... [Read More]
Thumbnail
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving... [Read More]
Sarepta Therapeutics Inc. ... [Read More]
CAMBRIDGE, Mass., Sept. 29, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development. [Read More]
Sarepta Therapeutics Inc. ... [Read More]
PTC Therapeutics Inc. ... [Read More]
Chief Executive Officer... [Read More]
President, CE... [Read More]
FY2019 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Leerink Swann (SRPT) ... [Read More]
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $5.75, or 14 percent, at $46.83 in Wednesday's session. The catalyst for the rally ... [Read More]
Sept 6- Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed. [Read More]
Sept 6- Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of a fatal. [Read More]
Sarepta Therapeutics Inc. ... [Read More]
CAMBRIDGE, Mass., Aug. 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development. [Read More]
Loading...
Preview